Product Information
IMITREX 4 MG/0.5 ML PEN INJECT is a brand product labeled by GlaxoSmithKline LLC, priced at $463.0733 per ML under NDC 00173073900. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on Dec 28, 1992. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the sumatriptan market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 mg/.5mL
Manufacturer
GlaxoSmithKline LLCNDC
00173073900
Classification
Brand
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA020080FDA Approved
12/28/1992
TE Code
AB
On Market Since
4/6/2006
Pharmacological Classes
Price Statistics
The NADAC for IMITREX 4 MG/0.5 ML PEN INJECT has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $463.0733 per ML |
|---|---|
| All-time high | $463.7814 (May 13, 2026) |
| All-time low | $463.0733 (May 20, 2026) |
| 52-week high | $463.7814 |
| 52-week low | $463.0733 |
| Median price | $463.0733 |
| Average price | $463.3523 |
| Largest weekly change | -0.2% (May 20, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the sumatriptan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IMITREX 4 MG/0.5 ML PEN INJECT?
The current National Average Drug Acquisition Cost (NADAC) for IMITREX 4 MG/0.5 ML PEN INJECT, manufactured by GlaxoSmithKline LLC, is $463.0733 per ML (NDC 00173073900), effective Sep 30, 2026.
How has the price of IMITREX 4 MG/0.5 ML PEN INJECT changed over time?
Over the history we have for it, the NADAC for IMITREX 4 MG/0.5 ML PEN INJECT has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for IMITREX 4 MG/0.5 ML PEN INJECT?
Since Feb 18, 2026, the NADAC for IMITREX 4 MG/0.5 ML PEN INJECT has ranged from a low of $463.0733 (May 20, 2026) to a high of $463.7814 (May 13, 2026), with a median of $463.0733 per ML.
Are there cheaper alternatives to IMITREX 4 MG/0.5 ML PEN INJECT?
No other NADAC-published product currently shares the active ingredient and strength of IMITREX 4 MG/0.5 ML PEN INJECT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures IMITREX 4 MG/0.5 ML PEN INJECT?
IMITREX 4 MG/0.5 ML PEN INJECT (NDC 00173073900) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.